The U.S. Food and Drug Administration today approved the Amplatzer PFO Occluder device. The PFO Occluder reduces the risk of a stroke in patients who previously had a stroke believed to be caused by a blood clot that passed through a small hole in the heart, called a patent foramen ovale (PFO), and then traveled to the brain.
Back to Nature Issues a Product Recall and Allergy Alert for Chocolate Chunk Cookies, Mini Chocolate Chunk Cookies and Chocolate Granola Due to Undeclared Milk
Back to Nature Foods, LLC is voluntarily recalling four (4) products because those products contain chocolate purchased from a third party supplier which was found to contain undeclared Milk that is not listed as an ingredient on the label.
Read The Complete Story!
Stewart’s Shops Issues Allergy Alert On Undeclared Milk In Sportade Fruit Punch
Saratoga Springs, NY-Stewart’s Shops Corp. is recalling units of Stewart’s Sportade Fruit Punch Isotonic Beverage 20 fluid oz. because they may contain undeclared milk. People who have an allergy to milk run the risk of serious or life-threatening allergic reaction if they consume this product.
Brownwood Farms Issues Allergy Alert On Undeclared Milk In Fruit Preserves And Fruit Butter Products
Brownwood Farms of Williamsburg, MI is recalling approximately 260,000 total units of the listed products, because they contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction, if they consume these products.
Brownwood Farms Issues Allergy Alert On Undeclared Milk In Fruit Preserves And Fruit Butter Products
Brownwood Farms of Williamsburg, MI is recalling approximately 260,000 total units of the listed products, because they contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction, if they consume these products.
FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma
The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline (chemotherapy) is an appropriate treatment.
Yoma Myanmar Tea Co. Issues Allergy Alert on Undeclared Peanuts in Yoma Myanmar Tea Salad Snack
Yoma Myanmar Tea Co. of Allston, MA is voluntarily recalling the Yoma Myanmar brand “Tea Salad Snack” in Regular and Spicy, 7 oz., because the products may contain undeclared peanuts. People who have allergies to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products.
Medtronic Announces Voluntary Recall of its Pipeline Embolization Device, Alligator Retrieval Device, X-Celerator Hydrophilic Guidewire, Ultraflow and Marathon Flow Directed Micro Catheters
This voluntary recall is being conducted due to the potential separation and detachment of the polytetrafluoroethylene (PTFE) coating on parts of these devices. Should the PTFE separate from the delivery wire or stylets, PTFE particulate could enter the blood stream of the patient.
Voluntary Recall Notice of McCormick 24 oz. Club Size Original Taco Seasoning Mix Due to Unlabeled Milk Allergen
SPARKS, Md., October 5, 2016 – McCormick & Company, Incorporated is initiating a voluntary class I recall of 24 oz. Club Size McCormick® Original Taco Seasoning Mix, UPC 52100302461 with best by date codes between June 27, 2018 and September 16, 2018 due to an unlabeled milk allergen
FDA awards 21 grants to stimulate product development for rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 21 new clinical trial research grants totaling more than $23 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry with research spanning domestic and international clinical sites.